Abstract
Norovirus is one of the most common gastrointestinal pathogens and causes substantial morbidity and mortality worldwide. A serious consequence can be acute kidney injury (AKI), characterised by a rapid deterioration of kidney function. A quarter of all inpatients have AKI, which is associated with an increased risk of mortality. This study aimed to quantify the contribution of norovirus community transmission to AKI hospitalisations in England and its attributable cost.
We developed an age-structured deterministic compartmental dynamic transmission model for norovirus. We used a Bayesian approach to fit the model to multiple electronic health data sources, including hospitalisations and primary care records for AKI and gastroenteritis, as well as laboratory-confirmed norovirus surveillance data in England, from 2013-2019. We used Markov Chain Monte Carlo to estimate the effect of norovirus incidence on community-acquired AKI hospitalisations. We estimate 25.4% (95% CrI: 17.9-36.3%) of norovirus infections in people aged 65 years and above were linked to community-acquired AKI hospitalisations, amounting to 793,229 (95% CrI: 557,125-1,130,593) hospitalisations between 2013-2019. This represents 16.3% (95% CrI: 11.4-23.2%) of community acquired AKI hospitalisations in people aged 65 years and above over this period. The economic healthcare cost associated with norovirus-linked AKI admissions was estimated to be on average £343 million annually.
Gastroenteritis has previously been identified as an important risk factor for AKI in vulnerable patients. Our results suggest norovirus incidence in the community plays an important role in driving AKI hospitalisations in individuals aged 65 years and above. This is the first population-level estimate of the prevalence of norovirus infections linked to hospitalisations for AKI, and the comparable seasonal patterns between the two. This presents a substantial economic burden on the healthcare system and AKI hospitalisation should be an important consideration when evaluating future norovirus vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
An application for scientific approval related to the use of the Clinical Practice Research Datalink (CPRD) data has been approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory Agency in 2023 (protocol no. 23_003034). CPRD are already approved via a National Research Ethics Committee for purely non-interventional research of this type. The work undertaken has also had ethical approval from the London School of Hygiene & Tropical Medicine Observational/Interventions Research Ethics Committee (LSHTM Ethics ref: 22670)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The underlying data cannot be shared publicly because of the confidential nature of the data, and access is only provided to approved researchers. Access to primary care and hospitalisation data is available on request to the Clinical Practice Research Datalink (https://cprd.com/how-access-cprd-data). We developed an R package called noromod (https://github.com/pratikunterwegs/noromod) to execute the compartmental dynamic transmission model of norovirus. Model fitting, analysis code, and results are available at: https://github.com/ehr-lshtm/acute_kidney_injury_norovirus_transmission_model.
